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ORIGINAL ARTICLECharacterization and antimicrobial susceptibility of one
antibiotic-sensitive and one multidrug-resistant Corynebacterium
kroppenstedtii strain isolated from patients with granulomatous mastitisI. Fernández-Natal1,2, D. Rodríguez-Lázaro3, T. Marrodán-Ciordia1, J. A. Sáez-Nieto4, S. Valdezate4, H. Rodríguez-Pollán1,
A. Tauch5 and F. Soriano6
1) Department of Clinical Microbiology, Complejo Asistencial Universitario de León, 2) Institute of Biomedicine (IBIOMED), León, 3) Microbiology Section,
Department of Biotechnology and Food Science, Faculty of Science, University of Burgos, Burgos, 4) Bacterial Taxonomy Laboratory, Centro Nacional de
Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain, 5) Centrum für Biotechnologie (CeBiTec), Universität Bielefeld, Bielefeld, Germany and 6) Public
Health, School of Physiotherapy ONCE, Madrid, SpainAbstractHuman infections associated with Corynebacterium kroppenstedtii are rarely reported, and this organism is usually described as antibiotic
sensitive. Almost all published cases of C. kroppenstedtii infections have been associated with breast pathology in women and have been
described in New Zealand, France, Canada, India and Japan. Here we describe the microbiologic characteristics of two strains isolated
from two women diagnosed of granulomatous mastitis in Spain. One C. kroppenstedtii isolate was antibiotic sensitive while the other was
multidrug resistant. Biochemical identiﬁcation was possible using a wide battery of methods including API Coryne V2.0, API Strep, API
NH, API NE, matrix-assisted laser desorption/ionization time-of-ﬂight mass spectrometry and 16S rRNA gene ampliﬁcation and
sequencing. Antimicrobial susceptibility to 28 antibiotics as determined by Etest showed one isolate being sensitive to benzylpenicillin,
ciproﬂoxacin, moxiﬂoxacin, gentamicin, vancomycin, clindamycin, tetracycline, linezolid and rifampin. The second isolate showed
resistance to ciproﬂoxacin, moxiﬂoxacin, clindamycin, tetracycline and rifampin. The multidrug-resistant isolate contained the erm(X),
tet(W), cmx, aphA1-IAB, strAB and sul1 resistance genes known from the R plasmid pJA144188 of Corynebacterium resistens. These genes
were absent in the genome of the antibiotic-sensitive isolate. This report conﬁrms the tropism of this microorganism for women’s
breasts and presents the ﬁrst description of a multidrug-resistant C. kroppenstedtii strain.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
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E-mail: ifernandeznatal@gmail.comIntroductionCorynebacterium kroppenstedtii was ﬁrst described in 1998 as a
lipophilic species of the genus Corynebacterium lacking the© 2016 The Author(s). Published by El
This is an open access articharacteristic mycolic acids of the corynebacterial cell envelope
[1]. The description of this new species was based on one strain
isolated from the sputum of an 82-year-old woman with chest
infection and was deposited in the Culture Collection of the
University of Göteborg (CCUG, Sweden). Genome sequencing
of the type strain C. kroppenstedtii CCUG 35717 (DSM 44385)
revealed a contiguous genomic sequence with a total size of
2 446 804 bp and 2122 protein-coding regions [2]. The lack of
corynemycolic acids and the lipophilic lifestyle of
C. kroppenstedtii are caused by several events of gene loss,
including a condensate gene cluster and a mycolate reductase
gene, both involved in mycolic acid biosynthesis and a microbial
type I fatty acid synthase gene, resulting in a fatty acidNew Microbe and New Infect 2016; 14: 93–97
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Microbiome Project, C. kroppenstedtii is an abundant species in
the retroauricular crease [3], and it preferentially colonizes the
anterior nares and other distinct skin sites [4].
Since the description of the clinical isolate from Sweden,
which was used to characterize this new corynebacterial spe-
cies taxonomically, additional isolates of this organism from
human clinical sources have been reported in New Zealand
[5,6], France [7–10], Canada [11], India [12], Japan [13–15] and
Germany [16]. Eighty-eight percent of isolates have been ob-
tained from women’s breasts; the rest of the isolates came from
sputum [1,11], lung biopsy sample [11], blood [11] and endo-
cardiac valve [16]. From animal sources, a case of external otitis
associated with this organism was reported in a peach-faced
lovebird [17]. A comprehensive microbiologic and clinical re-
view of this organism has been published recently [18].
The aims of this work were to present the microbiologic
proﬁle of two C. kroppenstedtii strains, including their identiﬁ-
cation by matrix-assisted laser desorption/ionization time-of-
ﬂight mass spectrometry (MALDI-TOF MS) and 16S rRNA
gene sequencing, and to provide information on their antimi-
crobial susceptibility to 28 antibiotics. This analysis led to the
ﬁrst detection of a multidrug-resistant C. kroppenstedtii strain.Material and MethodsStrains characterized in this study
Two coryneform strains (CNM632/14 and CNM633/14) were
isolated in pure culture from clinical samples obtained by ﬁne
needle aspiration from the breast of two women, 38 and 45
years old, diagnosed with granulomatous mastitis and treated at
the Complejo Asistencial Universitario de León, Spain.
Phenotypic identiﬁcation of CNM632/14 and
CNM633/14
API Coryne V2.0 reactions (bioMérieux, Marcy l’Etoile, France),
API Strep (hippurate hydrolysis), API NH (fructose fermenta-
tion) and API NE (assimilation of maltose, N-acetyl-glucosamine
and phenylacetic acid) were used for the phenotypic charac-
terization of the corynebacterial isolates. In addition, catalase
and oxidase activity, lipophilia, Christie–Atkins–Munch–
Peterson (CAMP) reaction, glucose fermentation at 42°C,
growth on blood agar at 20°C and susceptibility to vibriostatic
factor O/129 were examined following previously described
methods [19]. MALDI-TOF MS was carried out with a Bruker
Biotyper system (Bruker Daltonics, Bremen, Germany). Soft-
ware version MBT 3.1 and the BDAL 5627 library were used
for the bacterial identiﬁcation. The direct colony method
including the spotting onto a MALDI-TOF MS target plate© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Micr
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licecovered with 1 μL of formic acid (100%) and 1 μL of matrix was
used as previously described [20]. Scores of 1.5 and 1.7
were used for genus and species identiﬁcation, respectively
[21].
Genotypic identiﬁcation and 16S rRNA gene sequences
Ampliﬁcation of the 16S rRNA genes and sequencing of the
PCR products were performed according to previously
described methods [22]. The 16S rRNA gene sequences of the
studied strains CNM632/14 and CNM633/14 were assigned the
GenBank accession numbers KP230546 and KP230545.
Antimicrobial susceptibility testing according to
EUCAST criteria
Antimicrobial susceptibility testing to 28 antimicrobials was
determined by Etest on Mueller-Hinton agar with 5% sheep’s
blood, incubated in air at 35°C and read after 48 hours. Sus-
ceptibility to antibiotics was interpreted following recom-
mended criteria by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) for coryneform organisms
(http://www.eucast.org/).ResultsIsolation of C. kroppenstedtii
Two coryneform strains, CNM632/14 and CNM633/14, were
obtained from samples taken from women’s breasts in pure
culture and grown on blood agar in air at 35°C for 48 hours.
Colonies were less than 1 mm in diameter, circular, smooth,
matte, nonpigmented and nonhaemolytic. The bacterial growth
was enhanced on blood agar supplemented with 1% (v/v)
Tween 80.
Species identiﬁcation by microbiologic and molecular
methods
Both strains presented the same API proﬁles after 24 hours
(2100104, maltose, sucrose and aesculin negative) and after 48
hours (2140104, maltose and sucrose negative, aesculin posi-
tive), suggesting Corynebacterium argentoratense and Corynebac-
terium jeikeium, respectively. Positive reaction was observed for
catalase, hippurate hydrolysis and pyrazinamidase and weak
reaction for alkaline phosphatase. Aesculin was weakly hydro-
lyzed after 48 hours. Acid was produced from glucose and
fructose but not from maltose, sucrose, ribose, xylose, lactose,
mannitol and glycogen. The microorganisms were negative for
oxidase, urease and nitrate reductase. Negative reactions were
also observed for gelatine hydrolysis, β-glucuronidase,
β-galactosidase, α-glucosidase, N-acetyl-β-glucosaminidase,
CAMP test and the assimilation of maltose, N-acetyl-obiology and Infectious Diseases, NMNI, 14, 93–97
nses/by-nc-nd/4.0/).
TABLE 1. Antimicrobial susceptibility of two Corynebacterium
kroppenstedtii strains to 28 antimicrobials
Antimicrobial
Strain 1 (CNM632/14) Strain 2 (CNM633/14)
MIC (mg/L) Categorya MIC (mg/L) Categorya
Benzylpenicillin 0.064 S 0.023 S
Ampicillin 0.047 NA <0.016 NA
Cefuroxime 0.75 NA 1 NA
Ceﬁxime >256 NA >256 NA
Cefotaxime 0.047 NA 0.023 NA
Imipenem 0.016 NA 0.047 NA
Vancomycin 0.75 S 0.38 S
Teicoplanin 1 NA 1 NA
Linezolid 0.064 S 0.064 S
Daptomycin 0.094 NA 0.25 NA
Tetracycline 1 S 32 R
Tigecycline 0.032 NA 0.064 NA
Chloramphenicol 0.75 NA >256 NA
Ciproﬂoxacin 0.094 S >32 R
Moxiﬂoxacin 0.064 S 1.5 R
Levoﬂoxacin 0.094 NA >32 NA
Erythromycin <0.016 NA >256 NA
Clarithromycin <0.016 NA >256 NA
Azithromycin 0.023 NA >256 NA
Clindamycin 0.032 S >256 R
Quinupristin–
dalfopristin
0.38 NA >32 NA
Streptomycin 0.75 NA 12 NA
Kanamycin 0.25 NA >256 NA
Gentamicin 0.016 S 0.032 S
Tobramycin 0.023 NA 0.032 NA
Amikacin 0.125 NA 0.125 NA
Rifampin <0.002 S <0.002 S
Cotrimoxazole 0.032 NA >32 NA
MIC, minimum inhibitory concentration; NA, not available; R, resistant;
S, susceptible.
aAccording to European Committee on Antimicrobial Susceptibility Testing
(EUCAST) susceptibility breakpoints (http://www.eucast.org/).
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by the O/129 factor (150 μg), showing an inhibition diameter of
30 and 42 mm, respectively.
Using MALDI-TOF MS as previously described, the two
coryneform strains gave signiﬁcant scores for C. kroppenstedtii
of 1.990 and 1.780 (data not shown). The sequenced DNA
fragments of the 16S rRNA gene were 1328 bp (CNM632/14)
and 1146 bp (CNM633/14) in length. The nucleotide sequence
similarities with GenBank sequences of C. kroppenstedtii were
99.4 and 100% to C. kroppenstedtii CIBU 090024 (JF299190)
from France [9], 99.1 and 99.7% to C. kroppenstedtii 00-0244
(AF537598) from Canada [11] and 99.0 and 99.7% to the type
strain C. kroppenstedtii DSM 44385 (CP001620) [2]. These data
clearly demonstrated that both clinical isolates obtained from
granulomatous mastitis can be assigned to the species
C. kroppenstedtii.
Antimicrobial susceptibility proﬁling of the new
C. kroppenstedtii isolates
The antimicrobial susceptibility data for the two
C. kroppenstedtii isolates tested against 28 antimicrobials are
presented in Table 1. Strain 1 (CNM632/14) showed, with the
exception of ceﬁxime, very low minimum inhibitory concen-
tration (MIC) values for the rest of the antibiotics tested.
However, the second strain (CNM633/14) showed high MIC
values for many antibiotics tested including ceﬁxime, erythro-
mycin, clarithromycin, azithromycin, clindamycin, quinupris-
tin–dalfopristin, tetracycline, chloramphenicol, ciproﬂoxacin,
levoﬂoxacin, streptomycin, kanamycin and cotrimoxazole.
Applying the EUCAST recommendations for antimicrobial
susceptibility, the ﬁrst isolate can be considered sensitive to
benzylpenicillin, ciproﬂoxacin, moxiﬂoxacin, gentamicin, van-
comycin, clindamycin, tetracycline, linezolid and rifampin. The
second isolate showed resistance to ciproﬂoxacin, moxi-
ﬂoxacin, clindamycin, tetracycline and rifampin.DiscussionGranulomatous mastitis is an inﬂammatory breast disease of
unknown aetiology that generally affects women of child-
bearing age, usually within a few years after they have given
birth [5,6]. The disease can become chronic and disﬁguring, and
it can be confused with a tumour. Mammary granulomas have
been associated with tuberculosis, sarcoidosis, fungal infections
and Wegener granulomatosis, but since 2002 it has also been
associated with infection by C. kroppenstedtii [5]. Our strains
were recovered from two patients with granulomatous
mastitis, representing the ﬁrst reported cases in Europe outside
of France. The breast is rich in lipids—a favourable condition© 2016 The Author(s). Published by Elsevier Ltd on behal
This is an open access articfor the development of lipophilic corynebacteria. Moreover, in
histologic sections of breast samples, the organism has been
located in vacuoles that probably contained lipids [5]. These
ﬁndings coincide with the evaluation of the genomic data of
C. kroppenstedtii which indicate that lipophilism (i.e. the de-
pendency of bacterial growth on the presence of lipids) is the
dominant feature involved in pathogenicity of C. kroppenstedtii
[2]. The role of this organism as a cause or complicating factor
of granulomatous mastitis has been demonstrated by several
authors [18], but such a disease seems to be a complex entity in
which the presence of C. kroppenstedtii could be just one piece
of an as-yet unsolved puzzle [18]. Further clinical and histo-
pathologic studies are still necessary to clarify its real role in
such a disease.
The new C. kroppenstedtii isolates showed the typical
phenotypic characteristics previously described for this
microorganism [18]. Identiﬁcation of this bacterium was ach-
ieved by phenotypic methods including the API Coryne
obtaining proﬁles of 2100104 and 2140104 after 24 and 48
hours respectively, with additional tests needed for a full
phenotypic identiﬁcation. Results of biochemical tests with
lipophilic corynebacteria should be interpreted after at least 48
hours of incubation, as acid production from carbohydrates and
aesculin hydrolysis might be delayed in many of these organismsf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 14, 93–97
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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two strains gave scores of 1780, which is considered reliable
to accurately identify the species [20,21]. Deﬁnitive identiﬁca-
tion was also obtained by sequencing the 16S rRNA gene
[18,22], and our two strains presented nucleotide sequence
similarities with GenBank sequences of C. kroppenstedtii from 99
to 100%. The species identiﬁcation was furthermore corrob-
orated by genome sequencing and the deduced genomic simi-
larity of both strains to the type strain C. kroppenstedtii DSM
44385 [2,24].
Using the Etest method and applying the EUCAST recom-
mendations for antimicrobial susceptibility of coryneform or-
ganisms (http://www.eucast.org/), the two C. kroppenstedtii
strains were found to be uniformly sensitive to penicillin, van-
comycin, linezolid, gentamicin and rifampin. One isolate was
resistant to tetracycline, ciproﬂoxacin, moxiﬂoxacin and clin-
damycin. It is striking that EUCAST, unlike the recommenda-
tions established by the Clinical and Laboratory Standards
Institute [25], has not yet deﬁned breakpoints for susceptibility
to erythromycin, although high MIC values are usually reported
for corynebacteria, and even genes coding for macrolide
resistance are often found [18].
The phenotypical novel multidrug resistance of
C. kroppenstedtii CNM633/14 was conﬁrmed when the
genome sequence was analysed and several antibiotic resis-
tance genes were annotated [24]. Interestingly, most of them
are located in a speciﬁc genomic island with similarity to the
R plasmid pJA144188, conferring multidrug resistance to
C. resistens DSM 45100 [26]. In addition, the genomic island
includes all insertion sequences previously described in
pJA144188. The gene content of the resistance island is fully
consistent with the antimicrobial susceptibility data (Table 1),
as erm(X), tet(W), cmx, aphA1-IAB, strAB and sul1 can confer
resistances to MLSb antibiotics, tetracyclines, chloramphen-
icol, aminoglycosides, streptomycin and sulfonamides in cor-
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